Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 123,566

Document Document Title
WO/2016/192687A1
The agents that inhibit system x c - provide the therapeutic intervention in substance-related and addictive disorders and the treatment and/or prevention in substance-mediated brain damage, and confirm that system x c -is a promising th...  
WO/2016/193235A1
The present invention relates to compounds of formula I wherein R1' is CH3; R1 is methyl, ethyl, CF3, cyclopropyl, CH2OH or R1' and R1 may form together with the carbon atom to which they are attached a 1,1- dioxo-thiolan-3-yl ring; R2 i...  
WO/2016/195526A1
The invention relates to veterinary science. A sedative composition with the effect of reducing sexual excitement in dogs and cats contains, in one dose per 10 kg body weight of the animal: 5-100 mg theanine; 2-16 mg tryptophan. The c...  
WO/2016/194131A1
[Problem] The purpose is to provide a ginsenoside composition derived from ginseng that is useful for use in oral compositions and body-related parenteral compositions. [Solution] A ginsenoside composition containing both CK and XVII, wh...  
WO/2016/196071A1
The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). Th...  
WO/2016/191869A1
There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which ...  
WO/2016/192667A1
Provided are a thiazolopyrimidinone compound represented by chemical formula (I), preparation method thereof, and use thereof in the preparation of drugs for treating central nervous system diseases, wherein X = O or S, Y = C or N, and w...  
WO/2016/192525A1
The present invention is directed to compounds, pharmaceutical compositions, and related methods of treatment and/or prevention for neurodegenerative diseases, such as Parkinson's disease.  
WO/2016/191855A1
The present invention relates to diene nitrile compounds with anti-convulsant activity and can also be used to treat pain. These compounds are useful in modulating voltage-gated sodium channel activity and can be used in the treatment of...  
WO/2016/196978A1
The present invention provides methods for treating a neurological disease such as ALS in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for treating neuroinflammati...  
WO/2016/194831A1
The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2016/197009A1
The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising...  
WO/2016/191312A1
The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated w...  
WO/2016/189087A1
The present invention relates to a pharmaceutical composition which includes a biocompatible polymer and a eukaryotic cell to be used as a drug for the prevention and/or treatment of tissue lesions of the central nervous system caused by...  
WO/2016/189876A1
The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing t...  
WO/2016/191418A1
The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selec...  
WO/2016/188816A1
The present invention relates to the compounds of formula I' for use in the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.  
WO/2016/190780A1
The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.  
WO/2016/189393A1
The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retain...  
WO/2016/190766A1
The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when ef...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/190263A1
Provided are: an excellent anti-human NGF antibody fragment that maintains high neutralizing activity and exhibits localized action while reducing systemic side effects from systemic exposure; and a therapeutic procedure for postoperativ...  
WO/2016/189501A1
Abstract of the invention: The present invention is related to a process for the large scale preparation of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor and also relates to polymorphs of that compound, and to m...  
WO/2016/187722A1
Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a...  
WO/2016/190002A1
The present invention addresses the problem of providing a donepezil-containing adhesive patch causing reduced skin irritability. The present invention is an adhesive patch including a support and an adhesive layer positioned on the supp...  
WO/2016/191351A1
Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.  
WO/2016/188972A1
The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused ...  
WO/2016/190750A1
Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta- casein to the animal for consumption, where the beta-casein c...  
WO/2016/188381A1
The present invention relates to the technical field of medical compounds, and relates to an oxidized β-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. In the present invention, by using abundant cellulose ...  
WO/2016/187718A1
A controlled extended release composition comprising at least one unit dosage form having at least one active pharmaceutical ingredient (API), wherein said at least one API comprises at least one of pregabalin, a base thereof, a pharmace...  
WO/2016/188684A1
The present invention refers to a process for preparing an animal brain extract. It also refers to the brain extract obtainable according to said process and to the use thereof as a medicine, in particular for the prevention and/or treat...  
WO/2016/189163A1
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3'-cyclic-nucleotide 3'-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagno...  
WO/2016/188828A1
Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for examp...  
WO/2016/190395A1
Provided is a composition that can be used to suppress microglia inflammation and is based on the discovery of oligopeptides that have a superior anti-inflammatory effect on microglia. The inflammation-suppressing action of dipeptides wa...  
WO/2016/190307A1
The present invention addresses the problem of finding a component that is capable of effectively exerting various effects of, for example, protecting brain function, preventing or ameliorating deterioration of cognitive ability and prev...  
WO/2016/188827A1
Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for examp...  
WO/2016/186772A3
Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non- naturally occurring Clustered Regularly Interspaced Short Palindro...  
WO/2016/187339A1
Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing the decline of Aβ amyloid in CSF or the ...  
WO/2016/184911A1
The present invention relates to methods and pharmaceutical compositions for the treatment of the neuropathology of patients suffering from myotonic dystrophy type 1 (DM1). In particular, the present invention relates to a method of trea...  
WO/2016/186154A1
It is found that the therapeutic efficacy of an IL-6 inhibitor on an MS patient can be predicted by employing, as a measure, the amount of plasmablasts and/or an index of a change of immature plasmablasts (e.g., the amount of immature pl...  
WO/2016/185468A1
The present invention provides pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid- responsive conditions and opioid-related side-effects.  
WO/2016/186140A1
The present invention addresses the problem of providing a novel membrane permeability-improving agent which can be applied to polymeric drugs. More specifically, the present invention addresses the problem of providing: a drug carrier w...  
WO/2016/184121A1
A new compound (as shown in formula I) and salts thereof, which are proved to be used for treating and preventing cerebral ischemic diseases and improving sleep by experiments. When R=H, salts are respectively generated by the compound t...  
WO/2016/185443A1
The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancemen...  
WO/2016/186967A1
The present disclosure provides indoleamine 2,3 -dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and R1 are as defined herein, as well as pharmaceutic...  
WO/2016/186184A1
The objective of the present invention is to provide: a crystal having high purity and excellent properties (such as stability and solubility) of a highly safe compound with few side effects, said compound having μ-opioid receptor antag...  
WO/2016/185160A1
A first aspect of the- invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is (CH2)mNR11R12;R2 is selected from H, halo, OR13, ΝΗR13, alkyl, alkenyl and alky...  
WO/2016/184310A1
The present invention relates to 4-methyl-1H-diaryl pyrazole derivatives, and specifically relates to the compounds represented by formula (I) and stereoisomers, solvates or pharmaceutically acceptable salts thereof. The present inventio...  
WO/2016/186204A1
Provided are a micelle for nucleic acid delivery using a temperature-sensitive polymer, and a method for producing the micelle. For example, provided is a polyion complex comprising a temperature-sensitive copolymer and a nucleic acid, w...  
WO/2016/185032A1
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more spec...  

Matches 701 - 750 out of 123,566